Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Moderna, Inc. (MRNA) Price & Performance

iShares iBoxx $ High Yield Corporate Bond ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ High Yield Corporate Bond ETF vs Moderna, Inc. — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.63, while Moderna, Inc. trades at $64.11 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

HYGMRNA
Sector
Fixed IncomeHealth
52-Week High
$81.32$81.80
52-Week Low
$78.72$22.36
Market Cap
$24.18B
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ High Yield Corporate Bond ETF

HYG, the iShares iBoxx $ High Yield Corporate Bond ETF, trades at $79.63 with minimal daily movement (+0.19%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent news highlights investor rotation into fixed income ETFs amid rising yields, though specific articles question HYG's competitiveness versus peers on expenses and performance.

The outlook for HYG is clouded by bearish technicals and mixed sentiment. Opportunities exist from high-yield demand, but risks include rising interest rates, inflation fears, and underperformance versus alternatives. Investors should weigh the ETF's 6.5% yield against potential downside from economic headwinds.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA